Kennedy Patrick T F, Zakaria Nada, Modawi Salma B, Papadopoulou Anthie M, Murray-Lyon Iain, du Bois Roland M, Jervoise N Andreyev H, Devlin John
Department of Gastroenterology, Chelsea and Westminster Hospital, London, UK.
Eur J Gastroenterol Hepatol. 2006 Jul;18(7):721-6. doi: 10.1097/01.meg.0000223911.85739.38.
Liver involvement in sarcoidosis is variable and can occur in the absence of pulmonary disease. Data on the natural history of hepatic sarcoid and response to therapy are lacking. This study investigates hepatic dysfunction complicating lung disease and significant liver involvement presenting independent of pulmonary sarcoid.
One hundred and eighty patients were included in the study. The minimum follow-up was 2 years.
Fifty per cent of the study population had derangement of liver function attributable to hepatic sarcoid. Twenty-three patients (13%) had liver involvement without lung disease. Sixty-three patients were administered corticosteroids; approximately one-third had a complete clinical response, one-third a partial response and one-third showed no response. Fourteen patients (8%) were cirrhotic at presentation, and two progressed to cirrhosis despite steroid therapy. Sixteen patients received a second-line immunosuppressive agent; one-half of these showed a response to treatment augmentation (four patients azathioprine, three patients methotrexate, one patient both drugs). Six patients required liver transplantation, with disease recurrence in one recipient. In four patients, sarcoid as the aetiology of end-stage liver disease was diagnosed only on examination of the explanted liver.
Sarcoidosis can cause end-stage chronic liver disease, which is often unrecognized until examination of the explanted liver. Response to conventional immunosuppression is variable and unpredictable. Transplantation is feasible and safe in this population but recurrence is possible.
结节病累及肝脏的情况各异,可在无肺部疾病时发生。目前缺乏关于肝结节病自然史及治疗反应的数据。本研究调查了合并肺部疾病的肝功能障碍以及独立于肺结节病的显著肝脏受累情况。
180例患者纳入本研究。最短随访时间为2年。
研究人群中50%的肝功能紊乱归因于肝结节病。23例患者(13%)肝脏受累但无肺部疾病。63例患者接受了皮质类固醇治疗;约三分之一有完全临床反应,三分之一有部分反应,三分之一无反应。14例患者(8%)初诊时已出现肝硬化,2例尽管接受了类固醇治疗仍进展为肝硬化。16例患者接受了二线免疫抑制剂治疗;其中一半对增加治疗有反应(4例使用硫唑嘌呤,3例使用甲氨蝶呤,1例两种药物均用)。6例患者需要肝移植,1例受者出现疾病复发。4例患者仅在对切除的肝脏进行检查时才诊断出结节病是终末期肝病的病因。
结节病可导致终末期慢性肝病,通常在对切除的肝脏进行检查时才被发现。对传统免疫抑制的反应多变且不可预测。移植对该人群可行且安全,但可能复发。